The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
Abstract
This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 584
Schlumberger, M. J., Vathaire, C. C.-D., de Vathaire, F., Travagli, J. P., Gardet, P., Lumbroso, J., Francese, C., Fontaine, F., Ricard, M., & Parmentier, C. (1996) · PubMed · Cited by 498
Barbet, J., Campion, L., Kraeber-Bodéré, F., & Chatal, J.-F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0044 · Cited by 407
Self-citationInvestigations of avidin and biotin for imaging applications.
Hnatowich, D. J., Virzi, F., & Rusckowski, M. (1987) · PubMed · Cited by 398
Voigt, C. (1984) · Cited by 392
Antibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Targeted therapy of cancer with radiolabeled antibodies.
Goldenberg, D. M. (2002) · PubMed · Cited by 318
Self-citationAntibodies against metal chelates
Reardan, D. T., Meares, C. F., Goodwin, D. A., McTigue, M., David, G. S., Stone, M. R., Leung, J. P., Bartholomew, R. M., & Frincke, J. M. (1985) · Nature · doi:10.1038/316265a0 · Cited by 260
Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.
Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., & Seccamani, E. (1991) · PubMed · Cited by 245
Self-citationChatal, J.-F., Campion, L., Kraeber-Bodéré, F., Bardet, S., Vuillez, J.-P., Charbonnel, B., Rohmer, V., Chang, C.-H., Sharkey, R. M., Goldenberg, D. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4917 · Cited by 232
Self-citationAxworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F.-M., Hobson, L. J., Beaumier, P. L., & Fritzberg, A. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1802 · Cited by 230
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
Paganelli, G., Grana, C., Chinol, M., Cremonesi, M., Cicco, C. D., de Braud, F., Robertson, C., Zurrida, S., Casadio, C., Zoboli, S., et al. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050397 · Cited by 218
Self-citationPretargeted radioimmunotherapy of cancer: progress step by step.
Boerman, O. C., van Schaijk, F. G., Oyen, W. J. G., et al. (2003) · PubMed · Cited by 216
Knox, S. J., Goris, M. L., Tempero, M. A., Weiden, P. L., Gentner, L., Breitz, H. B., Adams, G. P., Axworthy, D. B., Gaffigan, S., Bryan, K., et al. (2000) · PubMed · Cited by 212
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey, R. M., & Goldenberg, D. M. (2005) · PubMed · Cited by 200
Self-citationPress, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M., Gaynor, E. R., Rivkin, S. E., & Fisher, R. I. (2003) · Blood · doi:10.1182/blood-2003-01-0287 · Cited by 174
Grana, C., Chinol, M., Robertson, C., Mazzetta, C., Bartolomei, M., De Cicco, C., Fiorenza, M., Gatti, M., Caliceti, P., & Paganelli, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600047 · Cited by 168
Self-citationVose, J. M., Bierman, P. J., Enke, C., Hankins, J., Bociek, G., Lynch, J. C., & Armitage, J. O. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.117 · Cited by 161
Schubiger, P. A., Alberto, R., & Smith, A. (1996) · Bioconjugate Chemistry · doi:10.1021/bc950097s · Cited by 159
Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J. H., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., et al. (2004) · Blood · doi:10.1182/blood-2003-09-3284 · Cited by 155
Doussal, J. M. L., Martin, M., Gautherot, E., DELAAGE, M. A., & Barbet, J. (1989) · PubMed · Cited by 153
Self-citationThe Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M. J., Zelenetz, A. D., Wahl, R. L., Kroll, S., Coleman, M., Goris, M. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0756 · Cited by 152
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer
Bagshawe, K. D. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.10.1421 · Cited by 151
Breitz, H. B., Weiden, P. L., Beaumier, P. L., Axworthy, D. B., Seiler, C. A., Su, F., Graves, S. S., Bryan, K., & Reno, J. M. (2000) · PubMed · Cited by 151
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody
Sharkey, R. M., Cardillo, T. M., Rossi, E. A., Chang, C., Karacay, H., McBride, W. J., Hansen, H. J., Horak, I. D., & Goldenberg, D. M. (2005) · Nature Medicine · doi:10.1038/nm1322 · Cited by 148
Self-citationPress, O. W., Corcoran, M. C., Subbiah, K., Hamlin, D. K., Wilbur, D. S., Johnson, T., Theodore, L. J., Yau, E. K. C., Mallett, R. W., Meyer, D. L., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2535 · Cited by 148
Weiden, P. L., Breitz, H. B., Press, O. W., Appelbaum, J. W., Bryan, J. K., Gaffigan, S., Stone, D. M., Axworthy, D. B., Fisher, D. R., & Reno, J. M. (2000) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2000.15.15 · Cited by 141
Liersch, T., Meller, J., Kulle, B., Behr, T. M., Markus, P. M., Langer, C., Ghadimi, Β. M., Wegener, W. A., Kovacs, J., Horak, I. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.622 · Cited by 134
Self-citationMolecular advances in pretargeting radioimunotherapy with bispecific antibodies.
Chang, C., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., Hansen, H. J., Chatal, J., Barbet, J., & Goldenberg, D. M. (2002) · PubMed · Cited by 129
Self-citationKraeber‐Bodéré, F., Rousseau, C., Bodet‐Milin, C., Ferrer, L., Faivre-Chauvet, A., Campion, L., Vuillez, J.-P., Devillers, A., Chang, C., Goldenberg, D. M., et al. (2006) · PubMed · Cited by 122
Self-citationImproving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Sharkey, R. M., Karacay, H., Cardillo, T. M., Chang, C., McBride, W. J., Rossi, E. A., Horak, I. D., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0009 · Cited by 121
Self-citationIntraperitoneal radio‐localization of tumors pre‐targeted by biotinylated monoclonal antibodies
Paganelli, G., Pervez, S., Siccardi, A. G., Rowlinson, G., Deleide, G., Chiolerio, F., Malcovati, M., Scassellati, G. A., & Epenetos, A. A. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450632 · Cited by 109
Self-citationKraeber‐Bodéré, F., Bardet, S., Hoefnagel, C. A., Vieira, M. R., Vuillez, J.-P., Murat, A., Ferreira, T. C., Bardiès, M., Ferrer, L., Resche, I., et al. (1999) · PubMed · Cited by 105
Self-citationBarbet, J., PELTIER, P., Bardet, S., et al. (1998) · PubMed · Cited by 105
Self-citationStickney, D. R., Anderson, L., Slater, J. B., Ahlem, C. N., Kirk, G. A., Schweighardt, S., & Frincke, J. M. (1991) · PubMed · Cited by 103
Wong, J. Y. C., Shibata, S., Williams, L. E., Kwok, C. S., Liu, A., Chu, D. Z. J., Yamauchi, D. M., Wilczynski, S. P., Iklé, D. N., Wu, A. M., et al. (2003) · PubMed · Cited by 97
Advances in pretargeting biotechnology
Goodwin, D. A., & Meares, C. F. (2001) · Biotechnology Advances · doi:10.1016/s0734-9750(01)00065-9 · Cited by 81
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer
Bagshawe, K. D., Sharma, S. K., & Beǵent, R. H. J. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.11.1777 · Cited by 81
Gautherot, E., Rouvier, É., Daniel, L., Loucif, E., Bouhou, J., Manetti, C., Martin, M., Doussal, J. M. L., & Barbet, J. (2000) · PubMed · Cited by 75
Self-citationTumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha.
Moro, M., Pelagi, M., Fulci, G., Paganelli, G., Dellabona, P., Casorati, G., Siccardi, A. G., & Corti, A. (1997) · PubMed · Cited by 73
Self-citationBartolomei, M., Mazzetta, C., Handkiewicz-Junak, D., Bodei, L., Rocca, P. A., Grana, C. M., Maira, G., Sturiale, C. L., Villa, G., & Paganelli, G. (2004) · PubMed · Cited by 73
Self-citationShen, S., Forero, A., LoBuglio, A. F., Breitz, H. B., Khazaeli, M. B., Fisher, D. R., Wang, W., & Meredith, R. F. (2005) · PubMed · Cited by 70
OʼDonnell, R. T., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Kukis, D. L., DeNardo, G. L., & Meyers, F. J. (2001) · The Prostate · doi:10.1002/pros.10029 · Cited by 68
Behr, T. M., Memtsoudis, S. G., Sharkey, R. M., Blumenthal, R. D., Dunn, R. M., Gratz, S., Wieland, E., Nebendahl, K., Schmidberger, H., Goldenberg, D. M., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980831)77:5<787::aid-ijc19>3.0.co;2-z · Cited by 66
Self-citationSharkey, R. M., Hajjar, G., Yeldell, D., Brenner, A. J., Burton, J., Rubin, A. D., & Goldenberg, D. M. (2005) · PubMed · Cited by 64
Self-citationCurrent status of therapy of solid tumors: brain tumor therapy.
Zalutsky, M. R. (2005) · PubMed · Cited by 61
Griffiths, G. L., Chang, C., McBride, W. J., Rossi, E. A., Sheerin, A., Tejada, G. R., Karacay, H., Sharkey, R. M., Horak, I. D., Hansen, H. J., et al. (2004) · PubMed · Cited by 60
Self-citationKaracay, H., Brard, P.-Y., Sharkey, R. M., Chang, C., Rossi, E. A., McBride, W. J., Ragland, D. R., Horak, I. D., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1246 · Cited by 58
Self-citationClarke, K., Lee, F.-T., Brechbiel, M. W., et al. (2000) · PubMed · Cited by 57
Cheung, N. V., Modak, S. I., Lin, Y., Guo, H.-F., ZANZONICO, P. B., Chung, J., Zuo, Y., Sanderson, J., Wilbert, S. M., Theodore, L. J., et al. (2004) · PubMed · Cited by 56
Bardiès, M., Bardet, S., Faivre-Chauvet, A., PELTIER, P., Douillard, J.-Y., Mahé, M.-A., Fiche, M., Lisbona, A., Giacalone, F., Meyer, P., et al. (1996) · PubMed · Cited by 55
Self-citationGraves, S. S., Dearstyne, E., Lin, Y., Zuo, Y., Sanderson, J., Schultz, J., Pantalias, A., Gray, D., Axworthy, D. B., Jones, H. M., et al. (2003) · PubMed · Cited by 53
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.
Rossi, E. A., Sharkey, R. M., McBride, W., Karacay, H., Li, Z., Hansen, H. J., Goldenberg, D. M., & Chang, C. (2003) · PubMed · Cited by 52
Self-citationSharkey, R. M., Karacay, H., Chang, C., McBride, W. J., Horak, I. D., & Goldenberg, D. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403751 · Cited by 52
Self-citationOptimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey, R. M., Karacay, H., Richel, H., McBride, W. J., Rossi, E. A., Chang, K., Yeldell, D., Griffiths, G. L., Hansen, H. J., & Goldenberg, D. M. (2003) · PubMed · Cited by 51
Self-citationKaracay, H., Sharkey, R. M., McBride, W. J., Griffiths, G. L., Qu, Z., Chang, K.-M., Hansen, H. J., & Goldenberg, D. M. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0200172 · Cited by 50
Self-citationRossi, E. A., Chang, C., Losman, M. J., Sharkey, R. M., Karacay, H., McBride, W., Cardillo, T. M., Hansen, H. J., Qu, Z., Horak, I. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0020 · Cited by 50
Self-citationRadioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal
Sharkey, R. M., Burton, J., & Goldenberg, D. M. (2005) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.1.1.47 · Cited by 33
Self-citationMarrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
Breitz, H. B., Fisher, D. R., & Wessels, B. W. (1998) · PubMed · Cited by 32
Winter, J. N. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.s.005 · Cited by 27
Goldenberg, D. M., Juweid, M. E., Dunn, R. M., & Sharkey, R. M. (1997) · PubMed · Cited by 21
Self-citationAntibody-based therapies as anti-infective agents
Casadevall, A. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.3.307 · Cited by 13
Cited by
Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
Mitsunaga, M., Ogawa, M., Kosaka, N., Rosenblum, L. T., Choyke, P. L., & Kobayashi, H. (2011) · Nature Medicine · doi:10.1038/nm.2554 · Cited by 1,057
Tetrazine-Based Cycloadditions: Application to Pretargeted Live Cell Imaging
Devaraj, N. K., Weissleder, R., & Hilderbrand, S. A. (2008) · Bioconjugate Chemistry · doi:10.1021/bc8004446 · Cited by 858
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Metadata
- Authors
- Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., & Chatal, J.-F.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-02-10
- Volume
- 24
- Issue
- 5
- Pages
- 823-834
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2021396643
- Cited by
- 351
- References
- 65
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.